Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Taro Pharmaceutical Industries Ltd.    TARO   IL0010827181

TARO PHARMACEUTICAL INDUSTRIES LTD. (TARO)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 04/24 10:02:01 pm
101.51 USD   +0.01%
03/29TARO PHARMACEUT : Crescita Announces Launch of Pliaglis in U.S.
PR
02/09TARO PHARMACEUT : Provides Results for December 31, 2017
AQ
02/08TARO PHARMACEUT : posts 3Q profit
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Taro Pharmaceutical Industries Ltd. : Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/08/2012 | 11:25pm CEST

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today that it delivered a letter to one of its shareholders IsZo Capital Management LP ("IsZo") in response to IsZo's letter to Taro's Special Committee of the Board of Directors dated November 5, 2012. The full text of the letter is set forth below:

Re: Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

Dear Mr. Sheehy,

We at Taro are very appreciative of our shareholders' communications. More recently, our ability to respond to certain inquiries has been limited in light of the pending merger between Taro and Sun Pharma and the related shareholder meeting scheduled December 6, 2012. Rather, our management team's primary focus continues to be on Taro's core business, the performance of which speaks for itself.

Without responding to your many unfounded allegations over the past few months, I feel compelled to publicly correct one of your most recent statements. In your November 5th letter and corresponding press release, you contend that Taro is "gaming its reserves." Your allegation is simply untrue and your comment is, at a minimum, irresponsible to your fellow Taro shareholders.

As a NYSE listed company, Taro takes its financial accounting and reporting obligations very seriously. Although our quarterly financial reporting is presented on an unaudited basis, the accounting methodologies used in estimating our reserves are "consistently applied" quarter to quarter, in conformity with U.S. GAAP. Over the last couple of years, at the request of our Board and Audit Committee, we have taken an extra step by having our independent auditors perform certain "agreed upon procedures" on our financial statements focusing on specific areas, including reserves, prior to issuing our quarterly releases, including that for the quarter ended September 30, 2012.

Given your broad industry knowledge, you undoubtedly appreciate that, while IMS data is useful to the industry for general U.S. market intelligence and a general understanding of long term, product trends, it is not reliable (or prepared) for consolidated financial reporting analysis as you propose.

Finally, I recognize your excitement for Taro as expressed in your letter. I believe that all Taro shareholders have benefited tremendously at what the new management team, under the leadership of Mr. Shanghvi and, subsequently, Mr. Sundaram, have accomplished since the change in control in September 2010.

Sincerely,

/s/ Jim Kedrowski

Jim Kedrowski
Interim Chief Executive Officer

************************

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
VP, Treasurer
[email protected]


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TARO PHARMACEUTICAL INDUST
03/29TARO PHARMACEUTICAL INDUSTRIES : Crescita Announces Launch of Pliaglis in U.S.
PR
02/14TARO PHARMACEUTICAL INDUSTRIES : Provides Results for December 31, 2017
AQ
02/09TARO PHARMACEUTICAL INDUSTRIES : Provides Results for December 31, 2017
AQ
02/08TARO PHARMACEUTICAL INDUSTRIES : to Announce Third Quarter Results on February 7..
AQ
02/08TARO PHARMACEUTICAL INDUSTRIES : posts 3Q profit
AQ
02/07TARO PHARMACEUTICAL INDUSTRIES : Provides Results for December 31, 2017
BU
02/02TARO PHARMACEUTICAL INDUSTRIES : to Announce Third Quarter Results on February 7..
AQ
01/31TARO PHARMACEUTICAL INDUSTRIES : to Announce Third Quarter Results on February 7..
BU
2017TARO PHARMACEUTICAL INDUSTRIES : Provides Results for September 30, 2017
AQ
2017TARO PHARMACEUTICAL INDUSTRIES : posts 2Q profit
AQ
More news
News from SeekingAlpha
03/12Premarket analyst action - healthcare 
02/09YOUR DAILY PHARMA SCOOP : Adamas' Gocovri Key Value Driver, BioMarin Data, Regen.. 
02/07Taro Pharmaceutical reports Q4 results 
2017YOUR DAILY PHARMA SCOOP : Portola Upside, Novartis Reports Positive Cosentyx Dat.. 
2017Taro Pharmaceutical Industries' (TARO) CEO Uday Vijaykumar Baldota on Q2 2018.. 
Financials ($)
Sales 2018 733 M
EBIT 2018 382 M
Net income 2018 213 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 13,74
P/E ratio 2019 12,28
Capi. / Sales 2018 5,55x
Capi. / Sales 2019 5,60x
Capitalization 4 070 M
Chart TARO PHARMACEUTICAL INDUST
Duration : Period :
Taro Pharmaceutical Indust Technical Analysis Chart | TARO | IL0010827181 | 4-Traders
Technical analysis trends TARO PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 112 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Uday Vijaykumar Baldota Chief Executive Officer & Director
Dilip Shantilal Shanghvi Chairman
Itamar Karsenti Vice President & Operations Head-Haifa
Mariano Balaguer VP, Chief Financial & Accounting Officer
Avi Avramoff Global Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
TARO PHARMACEUTICAL INDUSTRIES LTD.-3.06%4 070
JOHNSON & JOHNSON-9.35%339 783
PFIZER1.13%217 897
NOVARTIS-7.72%204 972
ROCHE HOLDING LTD.-11.72%192 109
MERCK AND COMPANY7.07%158 571